Kurt R Brunden

Title: Kurt R Brunden: Innovator in Glycine Transport Inhibition

Introduction

Kurt R Brunden is a notable inventor based in Aurora, OH (US), recognized for his contributions to the field of glycine transport inhibition. With a total of four patents to his name, Brunden has made significant strides in developing pharmaceutical compositions that target glycine transporters, which play a crucial role in various disease states.

Latest Patents

Brunden's latest patents include innovative methods and compounds aimed at inhibiting high-affinity glycine transporters. One of his patents, titled "Substituted hydrazine derivatives," discloses compounds that inhibit these transporters and outlines their use in formulations for controlling or preventing disease states associated with glycine. Another significant patent, "Nitrogen-containing compounds and their use as glycine transport inhibitors," presents trichloroethyl-sulfonylurea-containing compounds that also inhibit glycine transporters. This patent details pharmaceutical compositions comprising these compounds and methods for their application in treating diseases related to glycine.

Career Highlights

Throughout his career, Kurt R Brunden has worked with prominent companies such as Gliatech, Inc. and Merck & Company, Inc. His experience in these organizations has contributed to his expertise in pharmaceutical development and innovation.

Collaborations

Brunden has collaborated with notable colleagues, including Syed M Ali and Jack B Jiang, further enhancing his research and development efforts in the field of glycine transport inhibition.

Conclusion

Kurt R Brunden's work in glycine transport inhibition showcases his innovative spirit and dedication to advancing pharmaceutical science. His patents and collaborations reflect a commitment to addressing critical health challenges through targeted therapies.